TCGX Acquisition Corp. (TCGX)
| Market Cap | 113.55M |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 11.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,168 |
| Open | 10.03 |
| Previous Close | 10.04 |
| Day's Range | 10.03 - 10.08 |
| 52-Week Range | 9.90 - 18.91 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About TCGX
TCGX Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was incorporated in 2026 and is based in Palo Alto, California.
News
TCGX Acquisition and TriGemX Bio submit draft registration statement
TCGX Acquisition (TCGX) and TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, announced the confidential submission of a draft r...
TriGemX Bio and TCGX Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)-- #Biotechnology--TriGemX Bio, Inc. (“TriGemX Bio”), a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for mi...
TCGX Acquisition, TriGemX Bio announce business combination agreement
TriGemX Bio and TCGX Acquisition (TCGX) Corp. announced the execution of a definitive business combination agreement that will result in TriGemX Bio becoming a publicly traded company. The combined co...
TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for Migraine
NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)-- #Biotechnology--TriGemX Bio, a biotechnology company focused on developing elismetrep, a potential first-in-class treatment for migraine, and TCGX Acqui...
TCGX Acquisition opens at $10.30, IPO priced at $10 per share
TCGX Acquisition (TCGX) Corp. priced its initial public offering of 7.5M Class A ordinary shares at a price of $10.00 per share. “Unlike certain other special purpose acquisition company initial…
TCGX Acquisition Corp. Announces Pricing of $75,000,000 Initial Public Offering
TCGX Acquisition Corp. announced today that it priced its initial public offering of 7,500,000 Class A ordinary shares at a price of $10.00 per share.
TCGX Acquisition IPO Registration Document (S-1)
TCGX Acquisition has filed to go public with an IPO on the NASDAQ